Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-142419

Published: 2020

Journal Articles

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Heather Stefanski, MD PhD, Claudio G Brunstein, MD PhD, David H. McKenna, MD, Darin Sumstad, MLS, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Glen D. Raffel, MD PhD, John C. Davis, Jr., MD MPH, MS, John E. Wagner, MD

Blood (2019) 134 (Supplement_1): 804.

https://doi.org/10.1182/blood-2019-122329

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Margaret L. MacMillan, MD, Keli Lee Hippen, PhD, David H. McKenna, MD, Todd E. DeFor, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Jeffrey S. Miller, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2018-99-113100

Published: 2018

Journal Articles

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Bartosz Grzywacz, MD, Elizabeth L. Courville, MD, David H. McKenna, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD, Laura Moench, MD

Blood (2017) 130 (Supplement 1): 4459.

https://doi.org/10.1182/blood.V130.Suppl_1.4459.4459

Published: 2017

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 2649.

https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649

Published: 2017

Journal Articles

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Frank Cichocki, PhD, Bahram Valamehr, PhD MBA, Dhifaf Sarhan, PhD, Bin Zhang, Sarah Cooley, MD, Michael R. Verneris, MD, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Betsy Rezner, BS, Paul Rogers, PhD, Chad Green, David H McKenna, MD, Daniel Shoemaker, PhD, Scott Wolchko, MS, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 1225.

https://doi.org/10.1182/blood.V128.22.1225.1225

Published: 2016

Journal Articles

Impact of Umbilical Cord Blood (UCB) T Regulatory Cells (Tregs) On Infection Risk Early After UCB Transplant

Claudio G Brunstein, MD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD, Qing Cao, MS, Keli Hippen, PhD, David H McKenna, MD, John E. Wagner, MD

Blood (2012) 120 (21): 4188.

https://doi.org/10.1182/blood.V120.21.4188.4188

Published: 2012

Journal Articles

Isolation and Characterization of Umbilical Cord Blood-Derived Multipotent Stem Cells Arising from Adherent CD45+/CD34+ Cell Subset.

David H. McKenna, MD, Sheryl Adams, MT (ASCP), Eileen Emrick, MT (ASCP), Stacey Sprague, MT (ASCP), Barbara M. Tigges, PhD, Daniel P. Collins, PhD

Blood (2005) 106 (11): 1064.

https://doi.org/10.1182/blood.V106.11.1064.1064

Published: 2005

NARROW

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Impact of Umbilical Cord Blood (UCB) T Regulatory Cells (Tregs) On Infection Risk Early After UCB Transplant

Isolation and Characterization of Umbilical Cord Blood-Derived Multipotent Stem Cells Arising from Adherent CD45+/CD34+ Cell Subset.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only